CLAIM LISTING:

Claims 1-59 (Canceled)

60. (New) A compound of the Formula I

$$R^1$$
 R^2
 R^3
 R^3
 R^3

or a pharmaceutically acceptable salt thereof, wherein:

X¹ is O, NR⁴ (where R⁴ is hydrogen or alkyl), S, or CR⁵R⁶ (where R⁵ and R⁶ are independently hydrogen or alkyl) or C=O;

Ar¹ is aryl or heteroaryl;

 R^2 is hydrogen alkyl, acyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkylcarbonyl, heteroalkyloxycarbonyl or $-R^{21}-R^{22}$ where R^{21} is alkylene or -C(=O)- and R^{22} is alkyl or alkoxy;

 R^1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkyl, heteroaralkyl, heteroalkyl, heteroalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, R^{12} -SO₂-heterocycloamino (where R^{12} is haloalkyl, aryl, aryalkyl, heteroaryl or heteroaralkyl), $-Y^1$ -C(O)- Y^2 - R^{11} (where Y^1 and Y^2 are independently either absent or an alkylene group and R^{11} is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), (heterocyclyl)(cycloalkyl)alkyl or (heterocyclyl)(heteroaryl)alkyl; and

R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, alkylene–C(O)–R³¹ (where R³¹ is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), amino, monoalkylamino, dialkylamino or NR³²-Y³-R³³ (where Y³ is –C(O), -C(O)O-, -C(O)NR³⁴, S(O)₂ or S(O)₂NR³⁵; R³², R³⁴ and R³⁵ are independently

hydrogen or alkyl; and R³³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl or optionally substituted phenyl) or acyl.

- 61. (New) The compound of Claim 1, wherein Ar¹ is optionally substituted phenyl.
 - 62. The compound of Claim 61, wherein X¹ is O or CH₂.
 - 63. The compound of Claim 62, wherein X^1 is O.
- 64. The compound of Claim 63 wherein R¹ is aryl, aralkyl, cycloalkyl, cycloalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, heterocyclyl or heterocyclylalkyl.
- 65. The compound of Claim 64, wherein R¹ is heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl or heterocyclyl.
 - 66. The compound of Claim 65, wherein R¹ is heterocyclyl.
 - 67. The compound of Claim 65, wherein R¹ is heteroalkyl.
 - 68. The compound of Claim 67, wherein R¹ is hydroxyalkyl.
- 69. The compound of Claim 65, wherein Ar¹ is 2-substituted-phenyl, 4-substituted-phenyl or 2,4-disubstituted-phenyl.
- 70. The compound of Claim 69, wherein Ar¹ is 2-chlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-fluoro-4-methylphenyl, 4-fluoro-2-methyl or 2,4-difluorophenyl.
 - 71. The compound of Claim 70, wherein R³ is methyl.

- 72. The compound of Claim 71, wherein R¹ is heteroalkyl substituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl or heterocyclyl.
- 73. The compound of Claim 72, wherein R¹ is heterocyclyl.
- 74. The compound of Claim 72, wherein R¹ is heteroalkyl.
- 75. The compound of Claim 72, wherein R¹ is hydroxyalkyl.
- 76. A method for treating p38 mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 60.
- 77. The method of Claim 76, wherein said p38 mediated disorder is arthritis, Crohns disease, irritable bowel syndrome, adult respiratory distress syndrome or chronic obstructive pulmonary disease.